Hostname: page-component-848d4c4894-xfwgj Total loading time: 0 Render date: 2024-06-17T07:48:20.352Z Has data issue: false hasContentIssue false

P0122 - Validation of a scale measuring patient satisfaction with psychotropic treatment (pasap) on a sample of schizophrenic patients - espass study

Published online by Cambridge University Press:  16 April 2020

I. Gasquet
Affiliation:
INSERM U669 Université Paris XI, Hôpital Cochin, Paris, France - Direction de la Politique Médicale, Assistance Publique - Hôpitaux de Paris, Paris, France
D. Legay
Affiliation:
Cesa.Me, Angers, France
J.M. Azorin
Affiliation:
Hôpital Sainte-Marguerite, AP-HM, Marseille Faculté de Médecine de Marseille, Marseille, France
J.Y. Loze
Affiliation:
Otsuka Pharmaceutical France, Rueil-Malmaison, France
L. Depret-Bixio
Affiliation:
HAYS Pharma, Paris, France
R. Arnaud
Affiliation:
Bristol-Myers Squibb Company, Rueil-Malmaison, France
F. Rouillion
Affiliation:
INSERM U669 Université Paris XI, Hôpital Sainte Anne, Université René Descartes Paris V, Paris, France

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background and Aims:

Patient satisfaction with treatment is a pertinent outcome for evaluating the effectiveness of psychotropic medication. The current study evaluated the psychometric properties of a new multi-item scale of PAtient SAtisfaction with Psychotropic treatment (PASAP).

Methods:

ESPASS is a, prospective, national observational study conducted in France on adult patients with schizophrenia (n=6007) requiring initiation or switch of antipsychotic medication. Demographics, psychiatric history, clinical status (CGI, IAQ) and pharmacological treatment patterns were recorded by psychiatrists at inclusion, 1, 3 and 6-months. Patients previously treated with an antipsychotic (n=4631) also completed a questionnaire on compliance, sexual problems, satisfaction with care and the 9-item PASAP scale (6 items evaluating their opinion of treatment and 3 items evaluating the prescriber). Each PASAP item is rated on a 5-point Likert scale. Patients who completed the 9-items were called PASAP completers.

Results:

63% of patients completed the PASAP scale at inclusion (2924/4631) and 53% at 6-months (2031/3829). PASAP completers were similar to non-completers for gender and marital status but were different for age, income level, duration of psychiatric care and severity of symptoms (p<0.001). Response rate to each item was ≥99%. At inclusion, principal component analysis suggested unidimensionality of the scale (Cronbach alpha=0.84). Inter-item correlation was satisfactory (>0.3) for most items. Responsiveness (sensitivity to change) at 6 months was good with the PASAP (effect size=0.731) and equivalent to the CGI (effect size=0.783).

Conclusion:

The psychometric characteristics of the PASAP scale are good. French and English versions are available free on request.

Type
Poster Session I: Schizophrenia and Psychosis
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.